UK markets open in 6 hours 5 minutes

Avadel Pharmaceuticals plc (AVDL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.68-0.34 (-4.24%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5449.18M
Enterprise value 3386.4M
Trailing P/E N/A
Forward P/E 1-48.00
PEG ratio (5-yr expected) 1-0.45
Price/sales (ttm)44.51
Price/book (mrq)3.29
Enterprise value/revenue 338.29
Enterprise value/EBITDA 7-8.36

Trading information

Stock price history

Beta (5Y monthly) 1.32
52-week change 3-9.86%
S&P500 52-week change 338.51%
52-week high 310.33
52-week low 34.83
50-day moving average 37.83
200-day moving average 37.89

Share statistics

Avg vol (3-month) 3258.92k
Avg vol (10-day) 3180.47k
Shares outstanding 558.49M
Implied shares outstanding 6N/A
Float 41.58M
% held by insiders 11.07%
% held by institutions 159.13%
Shares short (27 May 2021) 44.23M
Short ratio (27 May 2021) 415.25
Short % of float (27 May 2021) 4N/A
Short % of shares outstanding (27 May 2021) 47.23%
Shares short (prior month 29 Apr 2021) 43.91M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021

Profitability

Profit margin -55.02%
Operating margin (ttm)-472.35%

Management effectiveness

Return on assets (ttm)-11.90%
Return on equity (ttm)-6.59%

Income statement

Revenue (ttm)10.09M
Revenue per share (ttm)0.18
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)16.59M
EBITDA -46.21M
Net income avi to common (ttm)-5.55M
Diluted EPS (ttm)-0.10
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)206.45M
Total cash per share (mrq)3.53
Total debt (mrq)143.66M
Total debt/equity (mrq)105.24
Current ratio (mrq)26.57
Book value per share (mrq)2.33

Cash flow statement

Operating cash flow (ttm)-60.51M
Levered free cash flow (ttm)-68.01M